Akebia Therapeutics (AKBA) Reaches $16.74 52-Week High; Arlington Asset Investment (FBR) Sentiment Is 1.19

August 30, 2017 - By Peter Erickson

Fibria Celulose S.A. is a forestry company, which is engaged in the production of eucalyptus pulp. The company has market cap of $7.33 billion. The Firm is engaged in the production and sale of short fiber pulp from its pulp production facilities located in the cities of Aracruz (State of Espirito Santo), Tres Lagoas (State of Mato Grosso do Sul), Jacarei (State of Sao Paulo) and Eunapolis (State of Bahia). It has a 62809.52 P/E ratio. The Company’s activities are focused on the growth of renewable and forests, and the manufacture and sale of bleached eucalyptus kraft pulp.

The stock of Akebia Therapeutics Inc (NASDAQ:AKBA) hit a new 52-week high and has $17.58 target or 5.00% above today’s $16.74 share price. The 6 months bullish chart indicates low risk for the $789.31M company. The 1-year high was reported on Aug, 30 by Barchart.com. If the $17.58 price target is reached, the company will be worth $39.47M more. About 9,674 shares traded. Akebia Therapeutics Inc (NASDAQ:AKBA) has risen 76.80% since August 30, 2016 and is uptrending. It has outperformed by 60.10% the S&P500.

About 56,770 shares traded. Fibria Celulose SA (ADR) (FBR) has risen 16.20% since August 30, 2016 and is uptrending. It has underperformed by 0.50% the S&P500.

American Financial Group Inc holds 1.99% of its portfolio in Fibria Celulose SA (ADR) for 1.40 million shares. Grace & White Inc Ny owns 705,764 shares or 1.46% of their US portfolio. Moreover, Capital Innovations Llc has 1.01% invested in the company for 18,794 shares. The Illinois-based Bard Associates Inc has invested 0.46% in the stock. Cedar Hill Associates Llc, a Illinois-based fund reported 123,310 shares.

Akebia Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $789.31 million. The Firm focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor biology. It currently has negative earnings. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Among 7 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Akebia Therapeutics Inc has $26 highest and $10 lowest target. $20.33’s average target is 21.45% above currents $16.74 stock price. Akebia Therapeutics Inc had 19 analyst reports since August 13, 2015 according to SRatingsIntel. As per Monday, December 7, the company rating was initiated by H.C. Wainwright. The firm has “Overweight” rating given on Wednesday, September 9 by Morgan Stanley. The stock of Akebia Therapeutics Inc (NASDAQ:AKBA) earned “Neutral” rating by Credit Suisse on Thursday, January 21. The stock has “Buy” rating by Brean Capital on Thursday, September 29. The stock has “Buy” rating by H.C. Wainwright on Wednesday, August 9. Needham maintained the stock with “Buy” rating in Tuesday, December 15 report. The company was maintained on Monday, July 10 by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, November 15 by Aegis Capital. The company was maintained on Friday, June 30 by Aegis Capital. The firm has “Buy” rating by Brean Capital given on Wednesday, September 9.